Abstract | BACKGROUND: METHODS: RESULTS: Sixteen patients were treated at 3 dose levels. The MTD was defined as 10 g/m(2)/96 hours of ifosfamide and 800 mg/m(2)/96 hours of etoposide. Thirteen additional patients then were treated at 1 level below the MTD to try and decrease the interval between courses. A total of 12 of 29 patients developed a dose-limiting toxicity (DLT) after the first course of therapy. The most common DLT was gastrointestinal toxicity followed by hematologic toxicity. Twenty-seven patients developed standard National Cancer Institute criteria Grade 3 or 4 toxicity after the first course of treatment and 7 patients achieved a complete or partial response to the first course. The use of GM-CSF did not allow further dose intensification. CONCLUSIONS: This chemotherapy combination achieved a 31% overall response rate. A further increase in the dose intensity of this regimen may require supportive measures other than GM-CSF to decrease toxicity.
|
Authors | M C Fernandez, M D Krailo, R R Gerbing, K K Matthay |
Journal | Cancer
(Cancer)
Vol. 88
Issue 12
Pg. 2838-44
(Jun 15 2000)
ISSN: 0008-543X [Print] United States |
PMID | 10870069
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2000 American Cancer Society. |
Chemical References |
- Etoposide
- Doxorubicin
- Granulocyte-Macrophage Colony-Stimulating Factor
- Cisplatin
- Ifosfamide
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Cisplatin
(administration & dosage)
- Dose-Response Relationship, Drug
- Doxorubicin
(administration & dosage)
- Drug Administration Schedule
- Etoposide
(administration & dosage)
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor
(pharmacology, therapeutic use)
- Humans
- Ifosfamide
(administration & dosage)
- Infant
- Infant, Newborn
- Male
- Neuroblastoma
(drug therapy, pathology)
- Neutropenia
(chemically induced, prevention & control)
- Thrombocytopenia
(chemically induced, prevention & control)
- Treatment Outcome
|